Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/23/2007 First Published: 8/13/2006


1.		Phase I/II Study of E7389 in Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Renal Insufficiency

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CCC-PHII-75 7435, NCI-7435, NCT00365157

Last Modified: 4/13/2007 First Published: 4/23/2004


2.		Phase II Study of Fluorouracil, Leucovorin Calcium, Gemcitabine, and Cisplatin in Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Not specified				NCI				MDA-ID-030111 NCT00082706

Last Modified: 11/2/2006 First Published: 10/24/2006


3.		Phase II Study of Sunitinib Malate in Patients With Progressive Metastatic Transitional Cell Carcinoma of the Urothelium

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MSKCC-06081 NCT00397488


4.		Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				UMCC 2005.145 NCT00393796

Last Modified: 9/9/2008 First Published: 5/4/2007


5.		Phase II Study of Pazopanib Hydrochloride in Patients With Metastatic Urothelial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MCCRC-MC0553 7661, MC0553, NCT00471536


6.		Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				0609001823 NCT00461851

Last Modified: 6/28/2007 First Published: 5/21/2007


7.		Phase II Study of Gemcitabine Hydrochloride, Paclitaxel, Doxorubicin Hydrochloride, and Pegfilgrastim in Patients With Metastatic or Unresectable Transitional Cell Carcinoma of the Bladder or Urinary Tract and Renal Insufficiency

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Any age				NCI				MDA-2005-0839 MDA-2005-0939, 2005-0839, 7341, NCT00478361


8.		Randomized Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				UMCC 2007.097 NCT00645593


9.		A Phase II Study of AZD4877 (a Novel Anti-Mitotic Agent) in Advanced Bladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				D2782C00010 NCT00661609


10.		Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Over 18				Other, Pharmaceutical / Industry				2007-0704 NCT00749892

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute